Suppr超能文献

比较白内障术后抗炎方案对黄斑囊样水肿、虹膜炎、疼痛和畏光的发生率的影响。

Comparison of postcataract surgery anti-inflammatory regimens on the incidence of cystoid macular edema, iritis, pain, and photophobia.

机构信息

From the Eyes of York Cataract & Laser Center, York, Pennsylvania.

出版信息

J Cataract Refract Surg. 2023 Jan 1;49(1):44-49. doi: 10.1097/j.jcrs.0000000000001022.

Abstract

PURPOSE

To compare postcataract surgery anti-inflammatory regimens of intracanalicular dexamethasone insert and topical bromfenac on the incidence of cystoid macular edema (CME), iritis, pain, and photophobia.

SETTING

Eyes of York Cataract & Laser Center, York, Pennsylvania.

DESIGN

Retrospective chart review.

METHODS

Case records of 647 consecutive patients (1001 eyes) who underwent cataract surgery and received dexamethasone intracanalicular insert 0.4 mg (Group 1; 482 eyes) or topical nonsteroidal anti-inflammatory drug (NSAID) (bromfenac 0.075% 2 times a day) for 4 weeks postoperatively (Group 2; 519 eyes) were included. Both groups received intracameral moxifloxacin and phenylephrine/ketorolac. Patients with prior CME, vitreomacular traction, combined cataract/glaucoma surgery, and medication protocols different from those examined in this study were excluded.

RESULTS

Compared with the dexamethasone insert group, the topical NSAID group had a significantly lower incidence of CME (0.4% [2/519] vs 3.9% [19/482], P < .001) and photophobia (1.9% [10/519] vs 4.8% [23/482], P = .012). The incidence of breakthrough iritis (3.5% [18/519] vs 5.6% [27/482], P = .104) and pain also trended lower (4.0% [21/519] vs 5.4% [26/482], P = .314) in the topical NSAID group.

CONCLUSIONS

Topical NSAIDs were found to be more effective in controlling CME, pain, iritis, and photophobia after cataract surgery compared with the intracanalicular dexamethasone insert in the presence of intracameral phenylephrine/ketorolac.

摘要

目的

比较白内障术后巩膜隧道内注射地塞米松植入剂和局部使用溴芬酸钠治疗白内障术后炎症的方案对眼内炎、黄斑囊样水肿(CME)、眼痛和畏光的发生率的影响。

地点

美国宾夕法尼亚州约克白内障和激光中心的眼睛。

设计

回顾性图表审查。

方法

纳入 647 例(1001 只眼)连续白内障手术患者的病例记录,这些患者术后分别接受地塞米松巩膜隧道内植入剂 0.4mg(第 1 组;482 只眼)或局部非甾体抗炎药(溴芬酸钠 0.075%,每日 2 次)治疗 4 周(第 2 组;519 只眼)。两组均接受眼内注射莫西沙星和苯肾上腺素/酮咯酸。排除患有黄斑水肿、玻璃体黄斑牵引、白内障合并青光眼手术以及使用本研究未检查的药物方案的患者。

结果

与地塞米松植入剂组相比,局部使用 NSAID 组的 CME 发生率明显较低(0.4%[2/519] vs 3.9%[19/482],P<.001)和畏光(1.9%[10/519] vs 4.8%[23/482],P=.012)。局部使用 NSAID 组的爆发性眼内炎发生率(3.5%[18/519] vs 5.6%[27/482],P=.104)和疼痛发生率(4.0%[21/519] vs 5.4%[26/482],P=.314)也呈下降趋势。

结论

与巩膜隧道内地塞米松植入剂相比,在眼内注射苯肾上腺素/酮咯酸的情况下,局部使用 NSAID 对白内障术后 CME、疼痛、眼内炎和畏光的控制更为有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验